Length of stay

[키워드] member 13 a disintegrin and metalloproteinase with a thrombospondin type 1 motif acute respiratory syndrome ADAMTS-13a disintegrin and metalloproteinase with a thrombospondin type 1 motif American Society for Apheresis approach ARDSacute respiratory syndrome article ASFAAmerican Society for Apheresis available data benefit C-reactive protein Case series Case-control CCPCOVID-19 convalescent plasma Clinical outcome Coagulopathy conducted Controlled clinical trial coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent plasma COVID-19coronavirus disease 2019 criteria Critically ill patient CRPC-reactive protein CSS CSScytokine storm syndrome Cytokine storm syndrome Cytokines D-dimer Effects Evidence excessive immune response feasibility ferritin FFPfresh frozen plasma fibrinogen level fresh frozen plasma hypercoagulable Hyperinflammatory ICUIntensive Care Unit identify IFNinterferon ILInterleukin immunomodulatory effect improvement Inflammatory factor intensive care unit interferon interleukin interleukin-6 Intervention Length of stay LOSlength of stay Lymphocyte count macrophage activation syndrome management MASmacrophage activation syndrome MODSmultiple organ dysfunction syndrome Mortality multiple organ dysfunction syndrome offer offset PaO2:FiO2pressure of arterial oxygen to fractional inspired oxygen concentration pathologic Patient patients patients with COVID-19 peer-reviewed potential clinical benefits pressure of arterial oxygen to fractional inspired oxygen concentration prevent disease progression Randomized Randomized controlled trial RCTrandomized controlled trial reduce reduce mortality resulting risk role Safe SARS-CoV-2severe acute respiratory syndrome coronavirus 2 secondary hemophagocytic lymphohistiocytosis selected Sequential Organ Failure Assessment severe acute respiratory syndrome coronavirus 2 sHLHsecondary hemophagocytic lymphohistiocytosis SOFASequential Organ Failure Assessment TAMOFthrombocytopenia-associated multiple organ failure Therapeutic plasma exchange thrombocytopenia-associated multiple organ failure TNFTumor Necrosis Factor TPE TPEtherapeutic plasma exchange treat Treatment tumor necrosis factor while with COVID-19
[DOI] 10.1016/j.transci.2022.103433 [Article Type] Review article